Do analysts rate AVNS or SMTI?

Sanara MedTech has a consensus target price of $35.00, suggesting a potential upside of 0.86%. Given Sanara MedTech's stronger consensus rating and higher probable upside, analysts clearly believe Sanara MedTech is more favorable than Avanos Medical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Avanos Medical 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Sanara MedTech 1 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.80

Does the media refer more to AVNS or SMTI?

In the previous week, Avanos Medical had 3 more articles in the media than Sanara MedTech. MarketBeat recorded 5 mentions for Avanos Medical and 2 mentions for Sanara MedTech. Avanos Medical's average media sentiment score of 1.78 beat Sanara MedTech's score of 0.51 indicating that Avanos Medical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avanos Medical 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Sanara MedTech 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer QDEL or SMTI?

In the previous week, QuidelOrtho had 3 more articles in the media than Sanara MedTech. MarketBeat recorded 5 mentions for QuidelOrtho and 2 mentions for Sanara MedTech. QuidelOrtho's average media sentiment score of 1.49 beat Sanara MedTech's score of 0.51 indicating that QuidelOrtho is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment QuidelOrtho 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sanara MedTech 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, CERS or SMTI?

Cerus has higher revenue and earnings than Sanara MedTech. Cerus is trading at a lower price-to-earnings ratio than Sanara MedTech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cerus $221.55M 2.35 -$15.63M -$0.03 N/A Sanara MedTech $103.12M 3.09 -$37.56M -$3.59 N/A

Is CERS or SMTI more profitable?

Cerus has a net margin of -3.06% compared to Sanara MedTech's net margin of -29.15%. Sanara MedTech's return on equity of 29.72% beat Cerus' return on equity. Company Net Margins Return on Equity Return on Assets Cerus -3.06% -10.19% -3.14% Sanara MedTech -29.15% 29.72% 2.84%

Does the media favor CERS or SMTI?

In the previous week, Cerus had 2 more articles in the media than Sanara MedTech. MarketBeat recorded 4 mentions for Cerus and 2 mentions for Sanara MedTech. Cerus' average media sentiment score of 1.34 beat Sanara MedTech's score of 0.51 indicating that Cerus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cerus 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sanara MedTech 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, SMTI or EMBC?

Embecta has higher revenue and earnings than Sanara MedTech. Sanara MedTech is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sanara MedTech $103.12M 3.09 -$37.56M -$3.59 N/A Embecta $1.02B 0.32 $95.40M $1.48 3.83

Is SMTI or EMBC more profitable?

Embecta has a net margin of 8.59% compared to Sanara MedTech's net margin of -29.15%. Sanara MedTech's return on equity of 29.72% beat Embecta's return on equity. Company Net Margins Return on Equity Return on Assets Sanara MedTech -29.15% 29.72% 2.84% Embecta 8.59% -19.25% 10.82%

Does the media refer more to SMTI or EMBC?

In the previous week, Embecta had 1 more articles in the media than Sanara MedTech. MarketBeat recorded 3 mentions for Embecta and 2 mentions for Sanara MedTech. Sanara MedTech's average media sentiment score of 0.51 beat Embecta's score of 0.22 indicating that Sanara MedTech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sanara MedTech 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Embecta 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is RXST or SMTI more profitable?

Sanara MedTech has a net margin of -29.15% compared to RxSight's net margin of -36.80%. Sanara MedTech's return on equity of 29.72% beat RxSight's return on equity. Company Net Margins Return on Equity Return on Assets RxSight -36.80% -17.35% -14.70% Sanara MedTech -29.15% 29.72% 2.84%

Does the media prefer RXST or SMTI?

In the previous week, RxSight had 15 more articles in the media than Sanara MedTech. MarketBeat recorded 17 mentions for RxSight and 2 mentions for Sanara MedTech. RxSight's average media sentiment score of 1.09 beat Sanara MedTech's score of 0.51 indicating that RxSight is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment RxSight 11 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Sanara MedTech 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Sanara MedTech (SMTI) Competitors

$34.70 -0.10 (-0.29%)

As of 01:49 PM Eastern

Compare

SMTI vs. AVNS, QDEL, CERS, EMBC, and RXST

Should you buy Sanara MedTech stock or one of its competitors? Sanara MedTech's main competitors and comparable companies include Avanos Medical (AVNS), QuidelOrtho (QDEL), Cerus (CERS), Embecta (EMBC), and RxSight (RXST). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare supplies" industry.

How does Sanara MedTech compare to Avanos Medical?

Avanos Medical (NYSE:AVNS) and Sanara MedTech (NASDAQ:SMTI) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, media sentiment, profitability, valuation, analyst recommendations, institutional ownership, earnings and risk.

95.2% of Avanos Medical shares are held by institutional investors. Comparatively, 8.1% of Sanara MedTech shares are held by institutional investors. 2.3% of Avanos Medical shares are held by insiders. Comparatively, 42.0% of Sanara MedTech shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Avanos Medical has a beta of 1.57, indicating that its share price is 57% more volatile than the broader market. Comparatively, Sanara MedTech has a beta of 1.16, indicating that its share price is 16% more volatile than the broader market.

In the previous week, Avanos Medical had 3 more articles in the media than Sanara MedTech. MarketBeat recorded 5 mentions for Avanos Medical and 2 mentions for Sanara MedTech. Avanos Medical's average media sentiment score of 1.78 beat Sanara MedTech's score of 0.51 indicating that Avanos Medical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Avanos Medical	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Sanara MedTech	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Avanos Medical has a net margin of -10.39% compared to Sanara MedTech's net margin of -29.15%. Sanara MedTech's return on equity of 29.72% beat Avanos Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avanos Medical	-10.39%	5.39%	3.97%
Sanara MedTech	-29.15%	29.72%	2.84%

Sanara MedTech has lower revenue, but higher earnings than Avanos Medical. Avanos Medical is trading at a lower price-to-earnings ratio than Sanara MedTech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avanos Medical	$715.90M	1.64	-$72.90M	-$1.61	N/A
Sanara MedTech	$103.12M	3.09	-$37.56M	-$3.59	N/A

Sanara MedTech has a consensus target price of $35.00, suggesting a potential upside of 0.86%. Given Sanara MedTech's stronger consensus rating and higher probable upside, analysts clearly believe Sanara MedTech is more favorable than Avanos Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avanos Medical	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Sanara MedTech	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

Summary

Avanos Medical beats Sanara MedTech on 8 of the 15 factors compared between the two stocks.

How does Sanara MedTech compare to QuidelOrtho?

QuidelOrtho (NASDAQ:QDEL) and Sanara MedTech (NASDAQ:SMTI) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, risk, analyst recommendations, institutional ownership, valuation and earnings.

Sanara MedTech has lower revenue, but higher earnings than QuidelOrtho. Sanara MedTech is trading at a lower price-to-earnings ratio than QuidelOrtho, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
QuidelOrtho	$2.67B	0.35	-$1.13B	-$15.41	N/A
Sanara MedTech	$103.12M	3.09	-$37.56M	-$3.59	N/A

In the previous week, QuidelOrtho had 3 more articles in the media than Sanara MedTech. MarketBeat recorded 5 mentions for QuidelOrtho and 2 mentions for Sanara MedTech. QuidelOrtho's average media sentiment score of 1.49 beat Sanara MedTech's score of 0.51 indicating that QuidelOrtho is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
QuidelOrtho	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sanara MedTech	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

99.0% of QuidelOrtho shares are held by institutional investors. Comparatively, 8.1% of Sanara MedTech shares are held by institutional investors. 1.1% of QuidelOrtho shares are held by insiders. Comparatively, 42.0% of Sanara MedTech shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

QuidelOrtho has a beta of 0.68, suggesting that its stock price is 32% less volatile than the broader market. Comparatively, Sanara MedTech has a beta of 1.16, suggesting that its stock price is 16% more volatile than the broader market.

Sanara MedTech has a net margin of -29.15% compared to QuidelOrtho's net margin of -39.20%. Sanara MedTech's return on equity of 29.72% beat QuidelOrtho's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
QuidelOrtho	-39.20%	4.88%	1.63%
Sanara MedTech	-29.15%	29.72%	2.84%

QuidelOrtho currently has a consensus target price of $13.63, suggesting a potential downside of 1.27%. Sanara MedTech has a consensus target price of $35.00, suggesting a potential upside of 0.86%. Given Sanara MedTech's stronger consensus rating and higher possible upside, analysts plainly believe Sanara MedTech is more favorable than QuidelOrtho.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
QuidelOrtho	3 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Sanara MedTech	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

Summary

Sanara MedTech beats QuidelOrtho on 10 of the 15 factors compared between the two stocks.

How does Sanara MedTech compare to Cerus?

Cerus (NASDAQ:CERS) and Sanara MedTech (NASDAQ:SMTI) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, analyst recommendations, media sentiment, profitability, risk and earnings.

Cerus presently has a consensus target price of $5.25, indicating a potential upside of 103.09%. Sanara MedTech has a consensus target price of $35.00, indicating a potential upside of 0.86%. Given Cerus' stronger consensus rating and higher possible upside, equities analysts clearly believe Cerus is more favorable than Sanara MedTech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cerus	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Sanara MedTech	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

Cerus has a net margin of -3.06% compared to Sanara MedTech's net margin of -29.15%. Sanara MedTech's return on equity of 29.72% beat Cerus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cerus	-3.06%	-10.19%	-3.14%
Sanara MedTech	-29.15%	29.72%	2.84%

Cerus has higher revenue and earnings than Sanara MedTech. Cerus is trading at a lower price-to-earnings ratio than Sanara MedTech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cerus	$221.55M	2.35	-$15.63M	-$0.03	N/A
Sanara MedTech	$103.12M	3.09	-$37.56M	-$3.59	N/A

Cerus has a beta of 1.79, suggesting that its stock price is 79% more volatile than the broader market. Comparatively, Sanara MedTech has a beta of 1.16, suggesting that its stock price is 16% more volatile than the broader market.

In the previous week, Cerus had 2 more articles in the media than Sanara MedTech. MarketBeat recorded 4 mentions for Cerus and 2 mentions for Sanara MedTech. Cerus' average media sentiment score of 1.34 beat Sanara MedTech's score of 0.51 indicating that Cerus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cerus	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sanara MedTech	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

78.4% of Cerus shares are held by institutional investors. Comparatively, 8.1% of Sanara MedTech shares are held by institutional investors. 5.3% of Cerus shares are held by company insiders. Comparatively, 42.0% of Sanara MedTech shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Cerus beats Sanara MedTech on 11 of the 16 factors compared between the two stocks.

How does Sanara MedTech compare to Embecta?

Sanara MedTech (NASDAQ:SMTI) and Embecta (NASDAQ:EMBC) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, earnings, institutional ownership, risk and profitability.

Sanara MedTech has a beta of 1.16, indicating that its share price is 16% more volatile than the broader market. Comparatively, Embecta has a beta of 0.86, indicating that its share price is 14% less volatile than the broader market.

Sanara MedTech currently has a consensus target price of $35.00, indicating a potential upside of 0.86%. Embecta has a consensus target price of $11.00, indicating a potential upside of 94.17%. Given Embecta's higher possible upside, analysts plainly believe Embecta is more favorable than Sanara MedTech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sanara MedTech	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80
Embecta	2 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.60

Embecta has a net margin of 8.59% compared to Sanara MedTech's net margin of -29.15%. Sanara MedTech's return on equity of 29.72% beat Embecta's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sanara MedTech	-29.15%	29.72%	2.84%
Embecta	8.59%	-19.25%	10.82%

8.1% of Sanara MedTech shares are owned by institutional investors. Comparatively, 93.8% of Embecta shares are owned by institutional investors. 42.0% of Sanara MedTech shares are owned by insiders. Comparatively, 1.3% of Embecta shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Embecta had 1 more articles in the media than Sanara MedTech. MarketBeat recorded 3 mentions for Embecta and 2 mentions for Sanara MedTech. Sanara MedTech's average media sentiment score of 0.51 beat Embecta's score of 0.22 indicating that Sanara MedTech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sanara MedTech	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Embecta	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Embecta has higher revenue and earnings than Sanara MedTech. Sanara MedTech is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sanara MedTech	$103.12M	3.09	-$37.56M	-$3.59	N/A
Embecta	$1.02B	0.32	$95.40M	$1.48	3.83

Summary

Embecta beats Sanara MedTech on 9 of the 15 factors compared between the two stocks.

How does Sanara MedTech compare to RxSight?

RxSight (NASDAQ:RXST) and Sanara MedTech (NASDAQ:SMTI) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, profitability, dividends, risk, analyst recommendations and media sentiment.

Sanara MedTech has a net margin of -29.15% compared to RxSight's net margin of -36.80%. Sanara MedTech's return on equity of 29.72% beat RxSight's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
RxSight	-36.80%	-17.35%	-14.70%
Sanara MedTech	-29.15%	29.72%	2.84%

RxSight currently has a consensus price target of $8.37, suggesting a potential upside of 25.70%. Sanara MedTech has a consensus price target of $35.00, suggesting a potential upside of 0.86%. Given RxSight's stronger consensus rating and higher possible upside, equities research analysts clearly believe RxSight is more favorable than Sanara MedTech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RxSight	3 Sell rating(s)	7 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.92
Sanara MedTech	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

In the previous week, RxSight had 15 more articles in the media than Sanara MedTech. MarketBeat recorded 17 mentions for RxSight and 2 mentions for Sanara MedTech. RxSight's average media sentiment score of 1.09 beat Sanara MedTech's score of 0.51 indicating that RxSight is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
RxSight	11 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Sanara MedTech	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

78.8% of RxSight shares are held by institutional investors. Comparatively, 8.1% of Sanara MedTech shares are held by institutional investors. 10.1% of RxSight shares are held by insiders. Comparatively, 42.0% of Sanara MedTech shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

RxSight has a beta of 1.16, meaning that its stock price is 16% more volatile than the broader market. Comparatively, Sanara MedTech has a beta of 1.16, meaning that its stock price is 16% more volatile than the broader market.

Sanara MedTech has lower revenue, but higher earnings than RxSight. Sanara MedTech is trading at a lower price-to-earnings ratio than RxSight, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RxSight	$127.58M	2.17	-$38.94M	-$1.13	N/A
Sanara MedTech	$103.12M	3.09	-$37.56M	-$3.59	N/A

Summary

RxSight beats Sanara MedTech on 9 of the 15 factors compared between the two stocks.

Get Sanara MedTech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SMTI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SMTI vs. The Competition

Export

Metric	Sanara MedTech	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$318.89M	$5.70B	$7.26B	$12.89B
Dividend Yield	N/A	1.75%	2.53%	8.56%
P/E Ratio	-9.67	25.86	273.79	25.41
Price / Sales	3.09	84.02	676.44	124.05
Price / Cash	58.51	33.05	76.98	52.08
Price / Book	40.35	6.06	12.87	6.16
Net Income	-$37.56M	$150.03M	$3.48B	$349.24M
7 Day Performance	0.35%	-1.22%	-0.27%	-1.43%
1 Month Performance	2.06%	3.35%	6.56%	2.51%
1 Year Performance	3.55%	7.45%	25.23%	15.93%

Sanara MedTech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SMTI Sanara MedTech	1.235 of 5 stars	$34.70 -0.3%	$35.00 +0.9%	+0.5%	$318.89M	$103.12M	N/A	60	High Trading Volume
AVNS Avanos Medical	0.5828 of 5 stars	$24.99 flat	N/A	N/A	$1.17B	$715.90M	N/A	2,287	Positive News
QDEL QuidelOrtho	1.8117 of 5 stars	$14.88 -1.1%	$13.63 -8.4%	-50.6%	$1.02B	$2.73B	N/A	6,500
CERS Cerus	2.325 of 5 stars	$2.73 +0.2%	$5.25 +92.7%	+104.7%	$549.14M	$206.13M	N/A	290	Positive News
EMBC Embecta	4.002 of 5 stars	$4.98 -1.1%	$11.00 +121.1%	-61.1%	$281.88M	$1.08B	3.36	1,850

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SMTI) was last updated on 9/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sanara MedTech (SMTI) Competitors

SMTI vs. AVNS, QDEL, CERS, EMBC, and RXST

How does Sanara MedTech compare to Avanos Medical?

Summary

How does Sanara MedTech compare to QuidelOrtho?

Summary

How does Sanara MedTech compare to Cerus?

Summary

How does Sanara MedTech compare to Embecta?

Summary

How does Sanara MedTech compare to RxSight?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SMTI vs. The Competition

Sanara MedTech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sanara MedTech (SMTI) Competitors

SMTI vs. AVNS, QDEL, CERS, EMBC, and RXST

How does Sanara MedTech compare to Avanos Medical?

Do insiders and institutionals hold more shares of AVNS or SMTI?

Which has more volatility and risk, AVNS or SMTI?

Does the media refer more to AVNS or SMTI?

Is AVNS or SMTI more profitable?

Which has higher valuation & earnings, AVNS or SMTI?

Do analysts rate AVNS or SMTI?

Summary

How does Sanara MedTech compare to QuidelOrtho?

Which has stronger valuation and earnings, QDEL or SMTI?

Does the media prefer QDEL or SMTI?

Do institutionals and insiders hold more shares of QDEL or SMTI?

Which has more volatility & risk, QDEL or SMTI?

Is QDEL or SMTI more profitable?

Do analysts rate QDEL or SMTI?

Summary

How does Sanara MedTech compare to Cerus?

Do analysts prefer CERS or SMTI?

Is CERS or SMTI more profitable?

Which has preferable earnings and valuation, CERS or SMTI?

Which has more risk and volatility, CERS or SMTI?

Does the media favor CERS or SMTI?

Do insiders & institutionals have more ownership in CERS or SMTI?

Summary

How does Sanara MedTech compare to Embecta?

Which has more risk & volatility, SMTI or EMBC?

Do analysts recommend SMTI or EMBC?

Is SMTI or EMBC more profitable?

Do institutionals and insiders believe in SMTI or EMBC?

Does the media refer more to SMTI or EMBC?

Which has stronger earnings and valuation, SMTI or EMBC?

Summary

How does Sanara MedTech compare to RxSight?

Is RXST or SMTI more profitable?

Do analysts recommend RXST or SMTI?

Does the media prefer RXST or SMTI?

Do insiders and institutionals have more ownership in RXST or SMTI?

Which has more risk and volatility, RXST or SMTI?

Which has better earnings & valuation, RXST or SMTI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SMTI vs. The Competition

Sanara MedTech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools